



If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

ITEM 7.01. REGULATION FD DISCLOSURE.

On August 8, 2018, the Company issued a press release titled “Chembio Diagnostics Reports Second Quarter 2018 Financial Results”. A copy of the press release is provided herewith as Exhibit 99.1.

On August 8, 2018, the Company posted a PowerPoint Presentation to its website titled “Corporate Presentation August 2018”. A copy of the presentation is provided herewith as Exhibit 99.2.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibits.

99.1 Press Release, dated August 8, 2018, titled “Chembio Diagnostics Reports Second Quarter 2018 Financial Results”.

99.2 Presentation, dated August 8, 2018, titled “Corporate Presentation August 2018”.

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

August 8, 2018 Chembio Diagnostics, Inc.

By: /s/ John J. Sperzel III  
John J. Sperzel III  
Chief Executive Officer

---

EXHIBIT INDEX

<u>Exhibit Number</u>	<u>Description</u>
<u>99.1</u>	Press Release, dated August 8, 2018, titled “Chembio Diagnostics Reports Second Quarter 2018 Financial Results”.
<u>99.2</u>	Presentation, dated August 8, 2018, titled “Corporate Presentation August 2018”.

---